$18.60+0.02 (+0.11%)
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States.
Progyny, Inc. in the Healthcare sector is trading at $18.60. The stock is currently near its 52-week low of $16.10, remaining 14.9% below its 200-day moving average. Technical signals show overbought RSI of 72 and bullish MACD crossover, explaining why PGNY maintains its current current market pressure. The Whystock Score of 10/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cyc...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PGNY vs. ALHC: Which Stock Is the Better Value Option?
Although the S&P 500 is down 2.1% over the past six months, Progyny’s stock price has fallen further to $17.17, losing shareholders 16.6% of their capital. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
If you are trying to figure out whether Progyny's current share price reflects its underlying worth, the key question is what you are really paying for at US$16.60 a share. The stock has recently been under pressure, with returns of a 3.9% decline over 7 days, a 5.8% decline over 30 days, and a 35.5% decline year to date, contributing to a 26.5% decline over 1 year and a 46.8% decline over 3 years. These moves have come as investors reassess the company and the broader healthcare space, with...